What patients and families need to know
TGF-beta in the Pathogenesis of Experimental Biliary Atresia
- Evan Nadler, M.D.
- Tatiana Iordanskaia, Ph.D.
We have previously shown that pre-treatment with our novel cyclophilin (Cyp) inhibitor, MM284, could prevent disease in the animal model of biliary atresia (BA) by decreasing SMAD phosphorylation and TIMP-4 and MMP-7 expression. We hypothesized that MM284 treatment after viral infection would be similarly effective, and in vitro MM284 could prevent Cyp stimulation of hepatic stellate cells (HSCs). Newborn Balb/c mice were randomized to receive an intraperitoneal injection with saline control or rhesus rotavirus (RRV) within 24 hours of birth. Animals receiving RRV were further randomized to receive either 20mg/kg i.p. of MM284 or control vehicle starting day of life 2, and then thrice weekly. Mice treated with MM284 were normal weight, had an approximately five-fold decrease in TIMP-4 and a tenfold decrease in MMP7 mRNA expression when compared to RRV mice. SMAD2/3 phosphorylation in the HSC lysates revealed a significant 1.5-fold increase after CypA treatment relative to untreated cells which was completed abrogated by MM284. These findings suggest that Cyp blockade may be a novel treatment strategy in not only BA, but other liver diseases that are putatively mediated by HSC activation.
Make an Appointment
Children's National in Your Neighborhood
Did you know we have 4 locations in Northern Virginia?
Find a Children's Location Near You
Find a Provider